on Takeda Pharmaceutical Company Limited (isin : JP3463000004)
Takeda Revises FY2024 Financial Forecasts
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced revised financial forecasts for the fiscal year ending March 31, 2025. The updated outlook projects increased revenue and profit figures compared to earlier estimates announced in May.
Takeda has adjusted its revenue forecast to JPY 4,480 billion, a 3.0% rise, largely due to milder-than-expected generic erosion of VYVANSE in the U.S. Operating profit is also expected to increase to JPY 265 billion, marking a 17.8% jump.
Further, the company's net profit forecast increased by 17.2% to JPY 68 billion, with a projected earnings per share of JPY 43.03. The firm attributes these revisions to improved business momentum and favorable forex assumptions.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Takeda Pharmaceutical Company Limited news